Dr. Kelley's studies have included examinations of longitudinal changes in bone and body composition in obese adolescents undergoing weight loss as well as in newly diagnosed children with type 1 diabetes. She has also conducted studies evaluating lipid abnormalities in high risk pediatric populations. Dr. Kelley's clinical and research interests within lipidology include familial hypercholesterolemia, hypertriglyceridemia and abnormal lipoprotein(a) in children. She is currently a local principal investigator for clinical trials, including use of PCSK-9 inhibitors in children with familial hypercholesterolemia. She also is a local principal investigator in the Type 1 Diabetes Exchange, a multi-institutional collaboration to improve the lives and care of patients with type 1 diabetes.

Dr. Jaser studies risk and protective factors in children and adolescents with type 1 diabetes. She has demonstrated the effects of adolescent coping, maternal adjustment, and parenting on adolescents' glycemic control and quality of life. She is currently developing and testing interventions to improve outcomes in youth with diabetes and their families. These include a program to help mothers cope effectively with the stress of parenting adolescents with type 1 diabetes, a positive psychology intervention to improve adolescents adherence, and sleep-promoting programs for children and adolescents with type 1 diabetes. In addition, she is interested in neurocognitive complications in pediatric type 1 diabetes.

>> View Publications on PubMed

Dr. Gregory's type 1 diabetes research seeks to mechanistically define the deleterious metabolic and cardiovascular effects of iatrogenic hyperinsulinemia caused by peripheral insulin delivery. He is working to translate these findings into therapeutic strategies that will restore an appropriate balance of insulin between the liver and insulin-sensitive peripheral tissues, such as hepatopreferential and oral insulin analogs and intraperitoneal insulin delivery. Ultimately, he aims to quantify the cardiovascular benefits gained when the appropriate insulin balance between hepatic and peripheral tissues is restored. Dr. Gregory's research utilizes the conscious, catheterized canine model to manipulate metabolic and hormonal conditions in vivo. He also conducts cardiometabolic research in humans in the Clinical Research Center at Vanderbilt.

>> View Publications on PubMed

Dr. Datye’s research focuses on learning about barriers to care that adolescents with type 1 diabetes face. She is also interested in developing interventions to improve adolescent self-management and ultimately glycemic control in this population. She has completed quality improvement training and uses these principles to guide her work in the endocrinology and diabetes clinics.

>> View Publications on PubMed

Dr. Russell studies ways to predict and to prevent type 1 diabetes (T1D) He is the Principal Investigator at Vanderbilt for the Type 1 Diabetes TrialNet consortium, which is funded by the National Institutes of Health to prevent type 1 diabetes in people at risk and to preserve insulin secretion in those who have T1D. He led the international abatacept trial (TN18) to determine whether an immune system modulating drug (CTLA4-Ig) can prevent the development of T1D in people at high risk to progress to full-blown T1D. He helped establish the Type 1 Diabetes Immunotherapy Clinic at the Monroe Carell Jr. Children’s Hospital at Vanderbilt to increase accessibility of newly FDA-approved therapies to patients for the delay and prevention of T1D. The Vanderbilt TrialNet Clinical Center was instrumental in demonstrating the effectiveness of the drug Tzield (teplizumab), the first of such agents FDA approved to delay progression to type 1 diabetes in individuals at risk.

>> View Publications on PubMed